PE20151726A1 - Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles - Google Patents

Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles

Info

Publication number
PE20151726A1
PE20151726A1 PE2015002122A PE2015002122A PE20151726A1 PE 20151726 A1 PE20151726 A1 PE 20151726A1 PE 2015002122 A PE2015002122 A PE 2015002122A PE 2015002122 A PE2015002122 A PE 2015002122A PE 20151726 A1 PE20151726 A1 PE 20151726A1
Authority
PE
Peru
Prior art keywords
imidazothiazoles
combination
macrocyclic lactones
veterinary formulations
stable veterinary
Prior art date
Application number
PE2015002122A
Other languages
English (en)
Inventor
Rose Guy Francis De
Sachin Pundlik Kolhe
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151726(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PE20151726A1 publication Critical patent/PE20151726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Referida a una composicion para el tratamiento de infecciones parasitarias en animales, que comprende: una lactona macrociclica tal como doramectina o moxidectina en una cantidad de entre 0,1% p/p a 1% p/p, de 4,0% p/p a 24% p/p de levamisol, un potenciador de estabilidad de aminoazucar tal como glucosamina o meglumina en una cantidad de entre 0,01% p/p a 0,2% p/p, un vehiculo farmaceutica o veterinariamente aceptable y al menos un agente antiparasitario adicional tal como benzimidazol
PE2015002122A 2013-04-12 2014-04-10 Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles PE20151726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361811138P 2013-04-12 2013-04-12

Publications (1)

Publication Number Publication Date
PE20151726A1 true PE20151726A1 (es) 2015-11-18

Family

ID=50694063

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002122A PE20151726A1 (es) 2013-04-12 2014-04-10 Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles

Country Status (11)

Country Link
US (1) US10307405B2 (es)
EP (1) EP2983712B1 (es)
BR (1) BR112015025875B1 (es)
CL (1) CL2015002976A1 (es)
CR (1) CR20150508A (es)
ES (1) ES2846820T3 (es)
MX (1) MX364170B (es)
NZ (1) NZ712345A (es)
PE (1) PE20151726A1 (es)
PL (1) PL2983712T3 (es)
WO (1) WO2014169092A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017010598A2 (pt) * 2017-05-19 2018-12-04 Flavio Alves Da Rocha composições veterinárias de liberação retardada para controle de ovos e larvas de helmintos nas fezes dos ruminantes, uso das composições, uso de antelmínticos com essa finalidade
BR112020010297A2 (pt) 2017-11-23 2020-11-17 Ceva Sante Animale composição para tratar infestações de parasitas
CA3109543C (en) * 2018-09-05 2023-05-23 Zoetis Services Llc Palatable antiparasitic formulations
SI3815677T1 (sl) 2019-10-30 2023-12-29 Krka, D.D., Novo Mesto Stabilni veterinarski sestavek, ki obsega moksidektin in imidakloprid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4144352A (en) 1977-12-19 1979-03-13 Merck & Co., Inc. Milbemycin compounds as anthelmintic agents
EP0165900A3 (de) 1984-06-08 1986-05-28 Ciba-Geigy Ag Neue Lactone, Verfahren zu ihrer Herstellung und ihre Verwendung in der Schädlingsbekämpfung
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
CA2407611A1 (en) 2000-04-27 2001-11-08 Sankyo Company, Limited 13-substituted milbemycin derivatives, their preparation and their use against insects and other pests
US7348417B2 (en) 2003-08-07 2008-03-25 Wyeth Method of purifying moxidectin through crystallization
US7671034B2 (en) * 2003-12-19 2010-03-02 Merial Limited Stabilized formulation of ivermectin feed premix with an extended shelf life
WO2006006021A2 (en) * 2004-06-28 2006-01-19 Glenmark Pharmaceuticals Limited Stabilized pharmaceutical compositions of preferably a statin
WO2006069580A1 (en) * 2004-12-30 2006-07-06 Cheminova A/S Oil-in-water formulation of avermectins
US7840123B2 (en) * 2007-06-21 2010-11-23 S.C. Johnson & Son, Inc. Diffusion device
ES2693696T3 (es) 2007-11-26 2018-12-13 Merial, Inc. Sistemas de disolventes para formulaciones de unción dorsal continua para combatir parásitos
WO2010021555A1 (en) * 2008-08-18 2010-02-25 Schering-Plough Animal Health Limited Anthelmintic compositions
UA108641C2 (uk) * 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
AU2011252987B2 (en) 2010-05-12 2013-05-02 Boehringer Ingelheim Animal Health USA Inc. Injectable parasiticidal formulations of levamisole and macrocyclic lactones
DK3351546T5 (da) * 2011-12-02 2024-08-12 Boehringer Ingelheim Vetmedica Gmbh Langtidsvirkende injicerbare moxidectinformuleringer

Also Published As

Publication number Publication date
PL2983712T3 (pl) 2021-05-31
EP2983712A1 (en) 2016-02-17
BR112015025875B1 (pt) 2021-06-29
WO2014169092A1 (en) 2014-10-16
US20160051524A1 (en) 2016-02-25
US10307405B2 (en) 2019-06-04
EP2983712B1 (en) 2020-11-25
BR112015025875A2 (pt) 2017-07-25
CR20150508A (es) 2015-11-18
ES2846820T3 (es) 2021-07-29
NZ712345A (en) 2016-04-29
CL2015002976A1 (es) 2016-05-06
MX2015014310A (es) 2016-02-16
MX364170B (es) 2019-04-15

Similar Documents

Publication Publication Date Title
NI201400842A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas.
CL2012002764A1 (es) Composicion veterinaria liquida que comprende fipronil, praziquantel, un agente activo regulador del crecimiento, amervectina o milbemicina, un vehiculo, y opcionalmente un inhibidor de la cristalizacion; y su uso para el tratamiento o prevencion de una infecion o infestacion parasitaria.
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
CR20120623A (es) Composiciones Farmacéuticas que comprenden Monohidrato de Lactato de 4-amino-5-Fluoro-3-[6-(4-Metil-Piperazin-1-Il)-1H- Bencimidazol-2-Il]-1H-Quinolin-2-Ona
NI201500118A (es) Imidazopiridazinas sustituidas
DOP2016000007A (es) Pirazolpiridinas sustituidas
SV2013004451A (es) Compuestos y su uso
NI201700078A (es) Pirazolpiridinaminas
CO2017011284A2 (es) Combinaciones antihelmínticas y métodos de uso de ellas
PE20151726A1 (es) Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles
UY35848A (es) Tienopirimidinas
AR099829A1 (es) Formulaciones veterinarias antihelmínticas estables
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
AR043044A1 (es) Composicion antihelmintica
CL2008001536A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente antimicrobiano como ciprofloxacino y un agente antioxidante como acido ascorbico, la concentracion de ciprofloxacino va desde 250 mg hasta 1 gr y desde 50 mg hasta 200 mg para acido ascorbico, en una unidad de dosis; y uso en infecciones urinarias.
NZ594610A (en) Injectable Anthelmintic Formulations cotaining levamisole and one or more macrocyclic lactones for controlling internal parasites in ruminants
AR100815A1 (es) Formulaciones parasiticidas transdérmicas, método, uso
TR201203087A2 (tr) Seftibüten ve klavulanik asit formülasyonları.
TR201203084A2 (tr) Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar.

Legal Events

Date Code Title Description
FD Application declared void or lapsed